Clinical Trial Update: Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain [Phase 4]

View source ↗

Summary

Phase 4 safety and pharmacokinetic study of EMBEDA in children ages 7-17 with moderate-severe pain; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Chronic Pain in Children

Drugs mentioned

• EMBEDA (morphine sulfate/naltrexone hydrochloride extended-release)

Snippet

Sponsor: Pfizer | Conditions: Moderate-severe Pain | Phase 4 | Status: TERMINATED | Results posted: 2020-07-10